The global diagnostic exosome biomarkers market is anticipated to reach USD 196.8 million by 2023. Diagnostic exosome biomarkers sales are anticipated to expand at a significant CAGR of 16.3% between 2023 to 2033. By 2033, the diagnostic exosome biomarkers market is expected to be worth USD 888.5 million.
The market growth can be attributed to the increasing prevalence of cancer, ongoing research on exosomes, and the rising number of clinical studies and trials in exosome-based research expected to spur the diagnostic exosome biomarkers market during the forecast period. Even though there is no FDA-approved clinical exosome product, the number of clinical trials using exosome-based medicines and diagnostics continues to rise.
There has been a rise in studies focusing on comprehending the functionality of exosomes in diseases, especially cancer. Exosomes are associated with several cancer hallmarks that affect tumor spread, immunological regulation, and therapeutic hallmarks.
| Attributes | Diagnostic Exosome Biomarkers Industry (From 2018 to 2022) |
|---|---|
| CAGR | 14.5% |
| Market Size - 2018 | USD 100.07 million |
| Market Size - 2022 | USD 172.1 million |
| Attributes | Diagnostic Exosome Biomarkers Industry (From 2023 to 2033) |
|---|---|
| CAGR | 16.3% |
| Market Size - 2023 | USD 196.8 million |
| Market Size - 2033 | USD 888.5 million |
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
From 2018 to 2022, the diagnostic exosome biomarkers business experienced substantial growth as research and development in exosome-based diagnostics surged.
Advances in technology and an increased understanding of exosomes' role in disease pathology led to identifying potential biomarkers for various conditions, including cancer, neurodegenerative disorders, and infectious diseases. As a result, the diagnostic exosome biomarkers industry witnessed rising investments, product launches, and collaborations between biotech companies and research institutions.
The diagnostic exosome biomarkers market is expected to enter a booming era from 2023 to 2033. With the validation of exosome biomarkers and their adoption in clinical settings, exosome-based tests are likely to become routine diagnostic tools.
The shift toward personalized and non-invasive diagnostics may boost market growth for diagnostic exosome biomarkers, as these tests offer early detection and monitoring capabilities. The expanding applications of exosome-based therapeutics are anticipated to fuel market expansion for diagnostic exosome biomarkers.
Challenges such as standardization, regulatory hurdles, and cost considerations must be addressed to ensure the sustainable growth of the diagnostic exosome biomarkers market in the coming decade.
Growing Investments in the Pharmaceutical Sector to Augment the Market Size
Most biopharmaceutical, pharmaceutical, and medical equipment manufacturers invest hugely in developing novel drugs and devices. Pharmaceutical companies make heavy research and development investments to produce high-quality and innovative products.
The introduction of new technologies is likely to benefit the diagnostic exosome biomarkers industry notably. Exotic devices, a new exosome isolation technology, were introduced recently and expanded significantly over time due to their various benefits, such as purity, high yield, and efficiency. The market is expected to flourish in the forecast period due to such factors.
Lack of Awareness and Strict Rules for Product Approval Hamper the Market
Lack of awareness and stringent rules for product approval are expected to hamper the market growth during the forecast period despite various developments in the market. Other factors hampering the market include a lack of unique biomarkers, inefficient separation techniques, and a need for high-resolution visualization equipment limiting understanding of exosomes.
The growing collaboration among diagnostic exosome biomarkers manufacturers is likely to counter the hampering factors and propel growth.
Increasing Demand for Specialized Testing Services to Expand Market Size
The diagnostic exosome biomarkers manufacturers are outsourcing specialized testing services like Liquid Chromatography-Mass Spectrometry, RNA sequencing, wet chemistry, gene expressions, and others earlier in the API process development cycle. These services are mainly used for structural elucidation of key impurities, removing class I and II solvents, removing column chromatography, and efforts toward overall cost reduction and process efficiency.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
| Category | Product |
|---|---|
| Leading Segment | Reagents & Kits |
| Market Share | 58.8% |
| Category | End User |
|---|---|
| Leading Segment | Diagnostic Centers |
| Market Share | 37.3% |
Reagents and kits lead the demand in the diagnostic exosome biomarkers market. The reagents are essential components used in various diagnostic procedures and research involving exosome biomarkers, making them a fundamental requirement for most applications.
The commercially available kits' convenience and time-saving aspects, including reagents and necessary protocols, attract researchers and clinicians, streamlining the experimental process. Moreover, the increasing adoption of exosome-based diagnostics in various fields, such as oncology and neurology has fueled the demand for efficient and standardized testing solutions, contributing to the popularity of reagents & kits in the market.
Diagnostic centers lead the diagnostic exosome biomarkers sales. The diagnostic centers are dedicated facilities specializing in various diagnostic tests, including advanced biomarker assessments. Their focus on accurate and timely diagnoses attracts many patients seeking cutting-edge diagnostic services.
The diagnostic centers often collaborate with research institutions and pharmaceutical companies, surging demand for exosome biomarker testing in clinical trials and drug development studies. These centers have a broader reach, serving patients from different medical backgrounds, making them a central hub for biomarker-based testing. Also, their expertise, accessibility, and collaborative efforts contribute to their leading position in the diagnostic exosome biomarkers market.
Extensive Research to Develop Key Breakthroughs for Cancer Treatment Fueling Growth Prospects
According to Future Market Insights, the application of exosomes in cancer diagnosis and the development of translational precision medicine is expected to be maximum across cancer institutes. A market share worth 38.4% is anticipated for this segment in 2023.
Exosomes have proven to be highly effective in detecting multiple cancers in their early stages, with a reasonably high degree of sensitivity and specificity. Their intrinsic characteristics provide a unique ability to bypass biological impediments, notably the blood-brain barrier, or BBB. Since exosomes can target particular cell types, the transmission of therapeutic agents by exosomes could be more efficient than other vectors.
| Countries | Value Share in the Global Market |
|---|---|
| North America | 52.6% |
| Europe | 30.6% |
North America is expected to dominate the global diagnostic exosome biomarkers industry during the forecast period. As of 2023, the region is expected to secure about 52.6% of global revenue. Domination of the region can be attributed to established players and the growing launch of products.
Such factors are expected to benefit the regional market in the forecast period.
As per the analysis, Europe is expected to be the second-leading diagnostic exosome biomarkers industry during the forecast period. In 2023, the region is likely to claim 30.6% of revenue. The development of the regional diagnostic exosome biomarkers market can be attributed to the increasing incidences of cancer across the region.
Another factor contributing to the development of the regional market is the government's increasing expenditure on healthcare infrastructure.
| Countries | Market CAGR (From 2023 to 2033) |
|---|---|
| China | 19.8% |
| India | 16.2% |
| Australia | 9.5% |
Asia Pacific is projected to witness maximum growth opportunities, the study reveals. The region's expansion can be attributed to the increasing demand from developing economies like India, China, and Japan. In addition, the rising healthcare expenditures by developing countries are likely to offer remunerative opportunities for market development in the coming time.
Other factors contributing to the market growth for diagnostic exosome biomarkers include the growing prevalence of chronic disorders, increasing healthcare expenditures, and an increasing number of exosome diagnostics. Due to such factors, the diagnostic exosome biomarkers business in the Asia Pacific is likely to expand in the forecast period.
| Countries | Value Share in Global Market |
|---|---|
| The United States | 48.3% |
| Germany | 8.7% |
| Japan | 4.2% |
Codiak Biosciences (USA), Exosome Diagnostics (USA), Evox Therapeutics (USA), ExoCoBio (South Korea), ILIAS Biologics (South Korea), Anjarium Biosciences (Switzerland), Xollent (USA), Craif (Japan), and Carmine Therapeutics (USA), are some of the emerging names in the global diagnostic exosome biomarkers market.
Update from the Industry:
Key diagnostic exosome biomarker manufacturers include AMS Biotechnology Limited, 101Bio, BioRegenerative Sciences, Inc., Cell Guidance Systems LLC, Codiak BioSciences, Evomic Science LLC, ExoCyte Therapeutics Pte Ltd, Exovita biosciences, Immune Therapy Holdings AB, Lonza Group, Norgen Biotek Corp., ReNeuron Group plc and Therapeutic Solutions International, Inc.
Novel Developments
| Company | Exo Therapeutics |
|---|---|
| Strategy | Exo Therapeutics Secures USD 78 million in Series B Financing |
| Details | In October 2021, Exo Therapeutics raised USD 78 million in series B financing to develop a new strategy for drugging enzymes. Exo has developed an indirect approach to inhibit enzymes by blocking their exosites. |
| Company | Bio-Techne inked |
|---|---|
| Strategy | Bio-Techne and Thermo Fisher Unite for ExoTRU Kidney Transplant Rejection Test |
| Details | In February 2022, Bio-Techne inked an exclusive agreement with Thermo Fisher Scientific for developing and commercializing the ExoTRU kidney transplant rejection test designed by Bio-Techne. This liquid biopsy test provides allograft health information suitable for clinical and research applications. |
The global market size to reach USD 888.5 million by 2033.
AMS Biotechnology Limited and Lonza Group are the top key players.
The global market is estimated to secure a CAGR 16.3% through 2033.
The rising costs are likely to limit market growth.
The reagents & kits segment is highly preferred in the global market.
| Market Size (2023) | USD 7.9 Billion |
|---|---|
| Market Projected Size (2033) | USD 13.3 Billion |
| Value CAGR (2023 to 2033) | 5.3% |
| Market Size (2023) | USD 8 billion |
|---|---|
| Market Size (2033) | USD 12.5 billion |
| Market CAGR (2023 to 2033) | 4.6% |
Explore In-vitro Diagnostics Devices Insights
View Reports
Diagnostic Exosome Biomarkers Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
